Partner Content Partner Content Prescient Announces Recent Appointments to the Senior Adviso... Prescient hires two new senior members to Advisory Team
Partner Content Partner Content Prescient hires senior members to Advisory PRESCIENT ADVISORY ANNOUNCES RECENT APPOINTMENTS
News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face